Survodutide

A once-weekly 29-amino-acid acylated dual agonist of the glucagon and GLP-1 receptors (CAS 2805997-46-8), developed by Boehringer Ingelheim and Zealand Pharma as BI 456906. The glucagon-receptor arm adds hepatic fat oxidation and energy expenditure to GLP-1-driven appetite suppression. Holds FDA Breakthrough Therapy designation for non-cirrhotic MASH with stage-2/3 fibrosis, based on Phase 2 biopsy-proven MASH resolution in up to 83% of treated participants. Phase 3 SYNCHRONIZE trials in obesity and MASH ongoing; not yet FDA-approved.